[Advances in Hemophilia A inhibitors].
作者信息
Wang S X, Yang R C
机构信息
Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):444-448. doi: 10.3760/cma.j.issn.0253-2727.2017.05.018.
Abstract
摘要
相似文献
1
[Advances in Hemophilia A inhibitors].[甲型血友病抑制物的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):444-448. doi: 10.3760/cma.j.issn.0253-2727.2017.05.018.
2
Correlation between factor VIII genotype and inhibitor development in hemophilia A.血友病A中凝血因子VIII基因型与抑制物产生之间的相关性。
Semin Thromb Hemost. 2000;26(2):167-71. doi: 10.1055/s-2000-9819.
3
Factor VIII inhibitors in patients with hemophilia A.
Acta Haematol. 1999;102(1):42-6. doi: 10.1159/000040966.
4
Clinicohematologic Profile of Patients With Factor VIII Inhibitors: A Case Series.伴有凝血因子 VIII 抑制物患者的临床血液学特征：病例系列
Clin Appl Thromb Hemost. 2015 Apr;21(3):246-50. doi: 10.1177/1076029614548720. Epub 2014 Aug 29.
5
Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.乙型血友病患者中因子 IX 抑制剂的检测是否比甲型血友病患者中因子 VIII 抑制剂的检测更罕见？简明系统评价。
Cardiovasc Hematol Disord Drug Targets. 2020;20(3):185-190. doi: 10.2174/1871529X20666200701104143.
6
The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.沙特血友病患者中凝血因子VIII和IX抑制剂的患病率：沙特全国血友病筛查项目的结果。
Medicine (Baltimore). 2017 Jan;96(2):e5456. doi: 10.1097/MD.0000000000005456.
7
Advances in hemophilia: experimental aspects and therapy.血友病的研究进展：实验研究与治疗
Hematol Oncol Clin North Am. 2010 Feb;24(1):181-98. doi: 10.1016/j.hoc.2009.11.003.
8
Studies on factor VIII activation potential in hemophilia A-plasma and its significance for the comprehension of hemophilia.
Eur J Pediatr. 1976 Oct 1;123(3):187-98. doi: 10.1007/BF00452096.
9
Hemodialysis in a patient with severe hemophilia A and factor VIII inhibitor.一名患有严重甲型血友病且存在凝血因子 VIII 抑制物的患者的血液透析
Hemodial Int. 2016 Oct;20(4):E11-E13. doi: 10.1111/hdi.12429. Epub 2016 May 5.
本文引用的文献
1
Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.重度甲型血友病初治患者的抑制剂开发：芬兰一项全国性多中心研究
Haemophilia. 2016 Sep;22(5):721-9. doi: 10.1111/hae.12974. Epub 2016 Jun 24.
2
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.A 随机对照试验VIII 因子和中和抗体在血友病 A.
N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.
3
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.人源化双特异性抗体在血友病 A 中模拟因子 VIII 的功能。
N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.
4
Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015.2015年6月20日至25日国际血栓与止血学会第二十五届大会摘要
J Thromb Haemost. 2015 Jun;13 Suppl 2(Suppl 2):1-997. doi: 10.1111/jth.12993.
5
The EPIC study: a lesson to learn.EPIC研究：一个值得汲取的教训。
Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23.
6
Toward optimal therapy for inhibitors in hemophilia.血友病中抑制物的优化治疗
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):364-71. doi: 10.1182/asheducation-2014.1.364. Epub 2014 Nov 18.
7
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.重组猪序列抗血友病因子VIII（OBI-1）在获得性血友病A患者中的疗效和安全性。
Haemophilia. 2015 Mar;21(2):162-170. doi: 10.1111/hae.12627. Epub 2015 Jan 27.
8
Impact of inhibitors on hemophilia A mortality in the United States.抑制剂对美国甲型血友病死亡率的影响。
Am J Hematol. 2015 May;90(5):400-5. doi: 10.1002/ajh.23957. Epub 2015 Feb 5.
9
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.血友病中根据凝血因子浓缩剂进行的抑制剂研发。欧洲血友病安全监测（EUHASS）项目的四年结果。
Thromb Haemost. 2015 May;113(5):968-75. doi: 10.1160/TH14-10-0826. Epub 2015 Jan 8.
10
Toward optimal therapy for inhibitors in hemophilia.针对血友病抑制剂的最佳治疗方法。
Blood. 2014 Nov 27;124(23):3365-72. doi: 10.1182/blood-2014-05-577643.
Zotero 插件